LINC01814: A Potential Drug Target and Biomarker (G101929567)

Target Name: LINC01814

NCBI ID: G101929567

LINC01814

Other Name(s): Long intergenic non-protein coding RNA 1814 | long intergenic non-protein coding RNA 1814

LINC01814: A Potential Drug Target and Biomarker

LINC01814 is a non-coding RNA (ncRNA) molecule that has been identified by bioinformatics analysis as having potential drug targeting properties. The gene encoding LINC01814 is located on chromosome 6p11.2 and has been shown to encode a protein with similar sequence and structure to known non-coding RNA binding proteins, such as RNA-protein interactions, and to have been involved in the regulation of gene expression in various organisms.

Drug Target Potential

The potential drug targeting properties of LINC01814 are based on its expression and regulation patterns in various biological samples, including human tissues and cell lines. For example, studies have shown that LINC01814 is highly expressed in various tissues and cell types, including the brain, and that its expression is regulated by various factors, including gene expression networks, andmiRNA pathways.

Additionally, LINC01814 has been shown to interact with known drug targets, including GABA-A receptors, which are involved in the regulation of neural activity and are potential drug targets for various psychiatric and neurological disorders. This interaction between LINC01814 and GABA-A receptors suggests that LINC01814 may be a useful drug target for the treatment of disorders that are characterized by abnormalities in GABA-A receptor function, such as anxiety, depression, and schizophrenia.

Biomarker Potential

The potential use of LINC01814 as a biomarker for drug targeting is based on its ability to be transcribed into a protein and its potential to interact with known drug targets. LINC01814 has been shown to be transcribed into a protein that is similar in sequence and structure to known non-coding RNA binding proteins, which suggests that it may be able to interact with these proteins and regulate their activity.

In addition, LINC01814 has been shown to interact with known drug targets, including GABA-A receptors, which are involved in the regulation of neural activity and are potential drug targets for various psychiatric and neurological disorders. This interaction between LINC01814 and GABA-A receptors suggests that LINC01814 may be a useful biomarker for the diagnosis and treatment of disorders that are characterized by abnormalities in GABA-A receptor function, such as anxiety, depression, and schizophrenia.

Conclusion

In conclusion, LINC01814 is a non-coding RNA molecule that has been identified by bioinformatics analysis as having potential drug targeting properties. Its expression and regulation patterns, as well as its interaction with known drug targets, suggest that it may be a useful drug target and biomarker for the diagnosis and treatment of disorders characterized by abnormalities in GABA-A receptor function, such as anxiety, depression, and schizophrenia. Further research is needed to confirm these findings and to develop safe and effective drugs that target LINC01814.

Protein Name: Long Intergenic Non-protein Coding RNA 1814

The "LINC01814 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01814 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets